Business Context and Reporting Period
This Form 8-K is a current report filed by AIT Therapeutics, Inc. (not Beyond Air, Inc.) on August 16, 2017, covering events occurring on August 7 and August 10, 2017. The company is a Delaware corporation developing inhaled Nitric Oxide (NO) product candidates for respiratory diseases.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and clinical trial milestones rather than financial performance.
Material Changes and Corporate Events
- Board Appointment: On August 10, 2017, Erick J. Lucera was elected as a director and appointed to the Audit Committee.
- Clinical Trial Initiation: On August 7, 2017, the company announced the dosing of the first patient in a Phase 2 trial for its inhaled NO product targeting Nontuberculous Mycobacteria (NTM) patients with Mycobacterium Abscessus Complex.
Guidance, Outlook, and Risks
Clinical Outlook:
- Phase 2 (NTM): A single-arm, open-label trial enrolling ten patients. Treatment involves 160 ppm inhaled NO for 30 minutes, 3-5 times daily over 21 days. Primary endpoint is safety; secondary endpoints include six-minute walk test and bacterial load. Data expected in Q4 2017.
- Phase 3 (Bronchiolitis): Ongoing trial in hospitalized infants. Data expected in the first half of 2018.
- Regulatory Filings: Anticipated for both indications prior to the end of 2019.
Risks and Contingencies:
- The company's drug discovery approach is unproven and may not lead to marketable products.
- Significant dependence on third parties for development, manufacturing, and distribution.
- Risks associated with patient enrollment and the early-stage nature of all product candidates.
- Forward-looking statements are subject to uncertainties that could cause actual results to differ materially.
Investor Verification Checklist
- Verify the company name discrepancy (filing is for AIT Therapeutics, Inc., not Beyond Air, Inc.).
- Confirm the enrollment progress and safety data from the Phase 2 NTM trial in Q4 2017.
- Monitor the Phase 3 bronchiolitis trial data release scheduled for H1 2018.
- Review the company's cash runway and funding status, as this 8-K does not disclose liquidity metrics.
- Assess the company's reliance on third-party collaborators for manufacturing and distribution.